GAPDH and prostate carcinoma: Each QD was conjugated to oligonucleotides complementary to either GAPDH (QD608), PTEN (QD693), or A20 (QD800) mRNA and were then mixed and applied simultaneously to LNCaP prostate cancer cells using the 1-step QD-FISH protocol.